Sales and Marketing
Reaching Patients Throughout the World
BioMarin is a multinational commercial biopharmaceutical company providing important therapeutic treatments to thousands of patients around the world who might otherwise go untreated.
Our global sales force continues to solidify the company's commercial presence in the United States and Europe and is rapidly expanding into other regions such as Latin America, the Middle East and Asia-Pacific. Headquartered in San Rafael, California, the company operates subsidiary offices in Europe, Latin America, the Middle East and Asia. Company representatives work closely with genetic centers to educate pediatricians and general practitioners about the signs and symptoms of MPS VI, Morquio A syndrome, and other lysosomal storage disorders. By raising awareness about these rare diseases, we hope that individuals with MPS and other lysosomal storage disorders will be referred more promptly to genetic centers for testing, diagnosis, and treatment.
The company's newest product, VIMIZIM™ (elosulfase alfa) for Morquio A syndrome (MPS IVA), was approved in five years after the IND filing and launched immediately upon approval by the FDA. Similarly, Kuvan® for PKU, was approved in just a little over three years after the IND filing. Both Naglazyme® and Aldurazyme® were successfully developed and commercialized in about five years--a rate far surpassing that of industry standards.